Suire Caitlin N, Leissring Malcolm A
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697 USA.
J Exp Neurol. 2021;2(1):10-15.
Alzheimer disease (AD) is a debilitating neurodegenerative disorder characterized by extracellular deposition of the amyloid β-protein (Aβ) and intraneuronal accumulation of the microtubule-associated protein, tau. Despite a wealth of experimental and genetic evidence implicating both Aβ and tau in the pathogenesis of AD, the precise molecular links between these two pathological hallmarks have remained surprisingly elusive. Here, we review emerging evidence for a critical nexus among Aβ, tau, and the lysosomal protease cathepsin D (CatD) that we hypothesize may play a pivotal role in the etiology of AD. CatD degrades both Aβ and tau , but the relevance of this lysosomal protease to these principally extracellular and cytosolic proteins, respectively, had remained undefined for many decades. Recently, however, our group found that genetic deletion of CatD in mice results in dramatic accumulation of Aβ in lysosomes, revealing that Aβ is normally trafficked to lysosomes in substantial quantities. Moreover, emerging evidence suggests that tau is also trafficked to the lysosome via chaperone-mediated autophagy and other trafficking pathways. Thus, Aβ, tau and CatD are colocalized in the lysosome, an organelle that shows dysfunction early in AD pathogenesis, where they can potentially interact. Notably, we discovered that Aβ42-the Aβ species most strongly linked to AD pathogenesis-is a highly potent, low-nanomolar, competitive inhibitor of CatD. Taking these observations together, we hypothesize that Aβ42 may trigger tauopathy by competitive inhibition of CatD-mediated degradation of tau-pathogenic forms of tau, in particular. Herein, we review the evidence supporting this hypothesis and explore the implications for the molecular pathogenesis of AD. Future research into these novel mechanistic links among Aβ, tau and CatD promises to expand our understanding of the etiology of AD and could potentially lead to novel therapeutic approaches for combatting this devastating disease of brain and mind.
阿尔茨海默病(AD)是一种使人衰弱的神经退行性疾病,其特征在于淀粉样β蛋白(Aβ)的细胞外沉积以及微管相关蛋白tau在神经元内的积累。尽管有大量实验和遗传学证据表明Aβ和tau都与AD的发病机制有关,但这两个病理标志之间精确的分子联系仍然令人惊讶地难以捉摸。在这里,我们回顾了关于Aβ、tau和溶酶体蛋白酶组织蛋白酶D(CatD)之间关键联系的新证据,我们推测这可能在AD的病因学中起关键作用。CatD可降解Aβ和tau,但几十年来,这种溶酶体蛋白酶分别与这些主要位于细胞外和细胞溶质中的蛋白质的相关性一直未明确。然而,最近我们的研究小组发现,小鼠中CatD的基因缺失会导致溶酶体中Aβ大量积累,这表明Aβ通常会大量转运至溶酶体。此外,新出现的证据表明,tau也通过伴侣介导的自噬和其他转运途径被转运至溶酶体。因此,Aβ、tau和CatD在溶酶体中共定位,溶酶体是一种在AD发病机制早期就出现功能障碍的细胞器,它们可能在其中相互作用。值得注意的是,我们发现Aβ42(与AD发病机制联系最紧密的Aβ种类)是一种高效、低纳摩尔浓度的CatD竞争性抑制剂。综合这些观察结果,我们推测Aβ42可能通过竞争性抑制CatD介导的tau降解(特别是tau的致病形式)来引发tau病变。在此,我们回顾支持这一假设的证据,并探讨其对AD分子发病机制的影响。对Aβ、tau和CatD之间这些新的机制联系的未来研究有望扩展我们对AD病因的理解,并可能导致对抗这种毁灭性脑和精神疾病的新治疗方法。